Mikulicz disease is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-systematic stress. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching authoritative experts and teams at home and abroad to provide accurate diagnosis and treatment plans. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immunodeficiencies that were previously difficult to treat have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored throughout the treatment process, and timely adjusted according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of Mikulicz disease. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.